The results of a study conducted by Oregon Health & Science University and published in the journal Emerging Infectious Diseases point to the need to routinely get updated vaccines, particularly for older individuals and those with underlying medical issues.
The virus is still circulating, it’s continuing to evolve, and it remains dangerous. Sooner or later, there will be another variant that evades the immunity we have already built up. Our study demonstrates that it’s worthwhile to update our immune repertoire.”- Fikadu Tafesse, Ph.D., co-senior author, associate professor of molecular microbiology and immunology, OHSU School of Medicine
Based on federal data, vaccination uptake has decreased in the United States as the epidemic has become less visible to the general population.
In the most recent trial, blood samples from 55 individuals were separated both before and after they got an improved vaccine starting last fall that targets the virus’s XBB.1.5 subvariant, which is part of the omicron variant.
In terms of the amount of antibodies produced and their capacity to neutralize both the original strain of SARS-CoV-2 and other variants that have arisen after the novel coronavirus arrived in late 2019, they discovered a robust response. Crucially, it seemed that the vaccination produced a robust defense against the JN.1 variety that is currently circulating widely around the globe, indicating that frequent vaccine updates will help combat new variants.
The findings represent yet another milestone in the SARS-CoV-2 virus’s development.
“Overall, this work strongly supports the use of the updated vaccine,” said co-senior author Marcel Curlin, M.D., associate professor of medicine (infectious diseases) in the OHSU School of Medicine and medical director of OHSU Occupational Health. “In the big picture, COVID-19 is not going away but lining up alongside the other common respiratory illnesses such as flu and RSV, which cause relatively mild disease for most people and a lot of harm to a few.”
OHSU was among the first, in contrast to most other research investigations, to evaluate if blood serum antibodies produced by vaccination might prevent the infection of a live virus in a biosafety level 3 laboratory.
Xammy Huu Nguyenla, Mastura Wahedi, Timothy Bates, and Mila Trank-Greene from OHSU are co-authors with Tafesse and Curlin.
more recommended stories
-
Can Dementia Risk be lowered by Mobile Health Coaching
Recent findings published in The Lancet.
-
AAP Updates Guidance on HIV Transmission via Breastfeeding
The way that people with HIV.
-
Bariatric Surgery May Prevent Breast Cancer in Obese Women
Researchers examined the relationship between women’s.
-
Trial Reveals Benefits of Diagnosing and Treating Hidden Asthma and COPD
A world-first clinical trial published in.
-
DNA Damage Triggers New Cell Death Pathway
Tumor cells are killed by chemotherapy,.
-
Comorbidities Worsen Sleep Quality in Multiple Sclerosis
Comorbidities in multiple sclerosis (MS) are.
-
Latitude and Skin Type-Based Vitamin D Guidelines
In a recent study published in.
-
AOMs Reduce CVD Risk in Obese Medicare Patients
Obesity is a leading cause of.
-
Dopamine Linked to Brain Development in ASD
Summary: A recent study links autism.
-
Microplastics in Human Blood: Cardiovascular Risk
An investigation disclosed in the esteemed.
Leave a Comment